Share this article and save a life!
Why are pharma companies betting big on AI clinical trial networks?
Iterative Health just closed a massive $77M Series C, led by Google Ventures and Intrepid Growth Partners.
The numbers tell an interesting story:
→ 100+ research sites across 4 continents
→ 40+ pharma and biotech partnerships
→ 3x higher patient enrollment rates
→ 2x faster site activation
→ 3 months less startup time for trials
But here’s what caught my attention:
They’re expanding from GI and hepatology into cardiology and obesity. Two of healthcare’s most expensive chronic conditions.
Think about this for a moment.
The average Phase 3 clinical trial costs $19 million and takes 3.5 years to complete. Patient recruitment accounts for nearly 30% of that timeline.
Iterative claims they’re randomizing more than two IBD patients every business day. That’s the kind of efficiency that makes CFOs smile and researchers breathe easier.
The real disruption? They’re not just speeding up trials, they’re fundamentally changing how we find and enroll patients.
Traditional recruitment: Wait for patients to come to academic centers.
AI-powered networks: Bring trials directly to community practices where patients already receive care.
With partnerships spanning GI Alliance, OneGI, and U.S. Heart & Vascular, they’re tapping into real-world patient populations that traditional trials often miss.
This isn’t just about technology. It’s about democratizing clinical research access.
When community physicians can offer trial participation alongside routine care, we solve two problems:
1. Faster drug development timelines
2. More diverse, representative trial populations
The $77M isn’t just funding a company. It’s funding a fundamental shift in how we bring new treatments to market.
For healthcare executives: Are you thinking about how AI-powered trial networks could accelerate your research programs?
For physicians: Could your practice become part of the solution to slow drug development?
The future of clinical research isn’t in ivory towers. It’s in the exam rooms where patients already trust their doctors.
♻️ Repost if you believe clinical trials need to meet patients where they are.
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
